Bulk Inquiry
PD123319 ditrifluoroacetate (Optically pure S-enantiomer)
- Parent CAS: 130663-39-7
- Optical Purity: 100% e.e.
- Soluble in water and DMSO
- MF: C31H32N4O3.2C2HF3O2
- MW: 736.66
Description
PD123319 ditrifluoroacetate is an optically pure S-enantiomeric angiotensin II type 2 (AT2) receptor antagonist.
AT2 receptors participate in vascular remodeling, neuronal development, inflammation, fibrosis and renin-angiotensin system signaling. PD123319 is a reference antagonist for separating AT2 receptor effects from AT1-mediated angiotensin II responses.
Key Features
- Selective AT2 receptor antagonist
- Optically pure S-enantiomeric pharmacology tool
- Blocks angiotensin II type 2 receptor signaling
- Useful for AT1 versus AT2 pathway discrimination
Applications
- AT2 receptor antagonist assays
- Renin-angiotensin system research
- Vascular remodeling and fibrosis models
- Angiotensin receptor subtype profiling
The opposite enantiomer, (R)-(-)-PD123319 ditrifluoroacetate (Axon 3890), is also available from Axon Medchem.
More Information
| Parent CAS No. | 130663-39-7 |
|---|---|
| Chemical Name | (S)-1-(4-Dimethylamino-3-methyl-benzyl)-5-diphenylacetyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid ditrifluoroacetate |
| SMILES | C1(C)C(N(C)C)=CC=C(CN2C3C[C@@H](C(O)=O)N(C(=O)C(C4C=CC=CC=4)C4C=CC=CC=4)CC=3N=C2)C=1.C(C(F)(F)F)(O)=O.C(C(F)(F)F)(O)=O |&1:13,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C31H32N4O3.2C2HF3O2/c1-21-16-22(14-15-26(21)33(2)3)18-34-20-32-25-19-35(28(31(37)38)17-27(25)34)30(36)29(23-10-6-4-7-11-23)24-12-8-5-9-13-24;2*3-2(4,5)1(6)7/h4-16,20,28-29H,17-19H2,1-3H3,(H,37,38);2*(H,6,7)/t28-;;/m0../s1 |
| InChiKey | GPKQIEZLHVGJQH-ZXVJYWQYSA-N |
| CID | 6604951 |
| Short Description | AT2 antagonist |
References
- G Boulay et al. Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa. Mol. Pharmacol. 1992, 41, 809.
- Heller, J. et al. Effect of PD 123319, an AT-2 antagonist, on renal function of the anesthetized dog: comparison with EXP 3174, an AT-1 blocker. Kidney Blood Press Res. 1997;20(5):297-301.
- Widdop R.E. et al. Central administration of PD 123319 or EXP-3174 inhibits effects of angiotensin II. Am. J. Physiol. 1993, 264, H117-125.
- Keiser, J.A. et al. Renal hemodynamic and excretory responses to PD 123319 and losartan, nonpeptide AT1 and AT2 subtype-specific angiotensin II ligands. J. Pharmacol. Exp. Ther. 1992, 262(3), 1154-1160.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1969 | Buloxibutid |
From Inquiry |
| 2191 | AR 244555 |
From $143.00 |
| 3102 | Losartan |
From $66.00 |
| 3103 | Telmisartan |
From $66.00 |
| 3104 | Candesartan cilexetil |
From $55.00 |
| 3105 | Olmesartan |
From $99.00 |
| 3106 | Valsartan |
From $83.60 |
| 3363 | Azilsartan |
From $66.00 |
| 3386 | AVE0991 |
From $165.00 |
| 3550 | Fimasartan |
From $88.00 |
| 3890 | (R)-(-)-PD123319 ditrifluoroacetate (Optically pure) |
From $154.00 |
